

A¹ 2. (Amended) The pharmaceutical composition for prevention, treatment or therapy according to claim 1, comprising suppressing the secondary degeneration of the nervous tissues caused by injuries to the nervous tissues or to the spinal cord.

3A. (Amended) The pharmaceutical composition for prevention, treatment or therapy according to claim 2 wherein disease causing the secondary degeneration of the nervous tissues is spinal cord injury.

A² 4. (Amended) The pharmaceutical composition for prevention, treatment or therapy according to claim 1 wherein said prevention, treatment or therapy is achieved by ameliorating paralysis or paraplegia.

5. (Amended) The pharmaceutical composition for prevention, treatment or therapy according to claim 4 wherein disease causing the paralysis or paraplegia is spinal cord injury.

6. (amended) The pharmaceutical composition for prevention, treatment or therapy according to any one of claims 1 -9 wherein the pharmaceutical composition is suitable for intravenous administration.

A³ 7. (amended) The pharmaceutical composition for prevention, treatment or therapy according to any one of claims 1 -9 wherein the pharmaceutical composition is suitable for a single intravenous infusion or for continuous intravenous administration.

A⁴ 15. (amended) A pharmaceutical composition comprising ginsenoside Rb₁, its metabolites or salt thereof for prevention, treatment or therapy of trauma or traumatic injuries.

16. (amended) The pharmaceutical composition according to claim 15 wherein the trauma or traumatic injuries is or are spinal cord injuries, neurotrauma, or head injuries.

A⁵ 21. (amended) A method for screening novel active compounds or compositions for prevention, treatment or therapy of diseases of the nervous tissues or the spinal cord comprising using ginsenoside Rb1 or its metabolites as a leading compound(s).

A⁶ 25~~24~~. Pharmaceutical compositions for prevention, treatment or therapy of diseases of the nervous tissues or the spinal cord as obtained by the method according to claim 21 or 22.

✓
Kindly add new claims 28-31, as follows:

10~~28~~. (new) The pharmaceutical composition for prevention, treatment or therapy according to claim 10⁹ wherein the pharmaceutical composition is suitable for intravenous administration.

11~~29~~. (new) The pharmaceutical composition for prevention, treatment or therapy according to claim 10⁹ wherein the pharmaceutical composition is suitable for a single intravenous infusion or for continuous intravenous administration.

A⁷ 24~~30~~. (new) Pharmaceutical compositions for prevention, treatment or therapy of diseases of the nervous tissues or the spinal cord as obtained by the method according to claim 23.

26~~31~~. (new) A method for screening novel brain cell-protective agents or nerve cell-protective agents comprising using ginsenoside Rb1 or its metabolites as a leading compound(s).

REMARKS

The Applicants appreciate the Examiner's thorough examination of the subject application. Applicants request reconsideration of the subject application based on the following amendments and remarks.